MX2016005173A - Un polimorfo estable de la sal de (2r)-4-oxo-4-[3-(trifluorometil) -5,6-dihidro[1,2,4]triazolo[4,3-a]pirazin-7(8h)-il]-1-(2,4,5-trif luorofenil)butan-2-amina con acido l-tartarico. - Google Patents
Un polimorfo estable de la sal de (2r)-4-oxo-4-[3-(trifluorometil) -5,6-dihidro[1,2,4]triazolo[4,3-a]pirazin-7(8h)-il]-1-(2,4,5-trif luorofenil)butan-2-amina con acido l-tartarico.Info
- Publication number
- MX2016005173A MX2016005173A MX2016005173A MX2016005173A MX2016005173A MX 2016005173 A MX2016005173 A MX 2016005173A MX 2016005173 A MX2016005173 A MX 2016005173A MX 2016005173 A MX2016005173 A MX 2016005173A MX 2016005173 A MX2016005173 A MX 2016005173A
- Authority
- MX
- Mexico
- Prior art keywords
- salt
- tartaric acid
- pyrazin
- triazolo
- butan
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a un polimorfo estable (Forma Z1) de la sal de (2R)-4-oxo-4-[3-(trifluorometil)-5,6-dihidro[152, 4]triazolo[4,3-a]pirazin-7(8H)-il]-1-(2s4,5-trifluorofenil)butan- 2-amina (sitagliptina) con ácido L-tartárico, de la fórmula 1, la cual es una forma muy estable del ingrediente farmacéutico activo de productos medicinales proyectados especialmente para el tratamiento de la diabetes tipo 2. La presente invención también se refiere a un método para la preparación del polimorfo estable (Forma Z1) de la sal de sitagliptina con ácido L-tartárico, y al uso del mismo para la preparación de una composición farmacéutica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CZ2013-842A CZ2013842A3 (cs) | 2013-11-01 | 2013-11-01 | Stabilní polymorf soli (2R)-4-oxo-4-[3-(trifluorometyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorofenyl)butan-2-aminu s kyselinou L-vinnou |
PCT/CZ2014/000125 WO2015062562A1 (en) | 2013-11-01 | 2014-10-30 | A stable polymorph of the salt of (2r)-4-oxo-4-[3-(trifiuoromethyl)-5,6- dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8h)-yl]-l-(2,4,54rifluorophenyl)butan-2-amine with l-tartaric acid |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016005173A true MX2016005173A (es) | 2016-07-08 |
Family
ID=52130030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016005173A MX2016005173A (es) | 2013-11-01 | 2014-10-30 | Un polimorfo estable de la sal de (2r)-4-oxo-4-[3-(trifluorometil) -5,6-dihidro[1,2,4]triazolo[4,3-a]pirazin-7(8h)-il]-1-(2,4,5-trif luorofenil)butan-2-amina con acido l-tartarico. |
Country Status (17)
Country | Link |
---|---|
US (1) | US9862723B2 (es) |
EP (1) | EP3063151B1 (es) |
JP (1) | JP2016535045A (es) |
KR (1) | KR20160078359A (es) |
CN (1) | CN105705505A (es) |
CZ (1) | CZ2013842A3 (es) |
EA (1) | EA030029B1 (es) |
ES (1) | ES2694350T3 (es) |
IL (1) | IL245263A0 (es) |
LT (1) | LT3063151T (es) |
MX (1) | MX2016005173A (es) |
PL (1) | PL3063151T3 (es) |
PT (1) | PT3063151T (es) |
TR (1) | TR201815737T4 (es) |
UA (1) | UA119655C2 (es) |
WO (1) | WO2015062562A1 (es) |
ZA (1) | ZA201602731B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ27898U1 (cs) * | 2015-01-13 | 2015-03-02 | Zentiva, K.S. | Krystalická modifikace 2 L-vínanu (3R)-3-amino-1-[3-(trifluormethyl)-6,8-dihydro-5H-[1,2,4,]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorfenyl)butan-1-onu |
CZ27930U1 (cs) * | 2015-01-13 | 2015-03-10 | Zentiva, K.S. | Krystalická modifikace 3 L-vínanu (3R)-3-amino-1-[3-(trifluormethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorfenyl)butan-1-onu |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
JO2625B1 (en) | 2003-06-24 | 2011-11-01 | ميرك شارب اند دوم كوربوريشن | Phosphoric acid salts of dipeptidyl betidase inhibitor 4 |
EP1708571A4 (en) * | 2004-01-16 | 2009-07-08 | Merck & Co Inc | NEW CRYSTALLINE SALTS OF A DIPEPTIDYLPEPTIDASE IV HEMMER |
US20090221592A1 (en) | 2005-07-25 | 2009-09-03 | Ellison Martha E | Dodecylsulfate Salt Of A Dipeptidyl Peptidase-Iv Inhibitor |
EP2599781A1 (en) | 2007-12-20 | 2013-06-05 | Dr. Reddy's Laboratories Ltd. | Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof |
-
2013
- 2013-11-01 CZ CZ2013-842A patent/CZ2013842A3/cs unknown
-
2014
- 2014-10-30 PL PL14815215T patent/PL3063151T3/pl unknown
- 2014-10-30 WO PCT/CZ2014/000125 patent/WO2015062562A1/en active Application Filing
- 2014-10-30 ES ES14815215.0T patent/ES2694350T3/es active Active
- 2014-10-30 JP JP2016527233A patent/JP2016535045A/ja active Pending
- 2014-10-30 UA UAA201605947A patent/UA119655C2/uk unknown
- 2014-10-30 EA EA201690869A patent/EA030029B1/ru not_active IP Right Cessation
- 2014-10-30 KR KR1020167011175A patent/KR20160078359A/ko not_active Application Discontinuation
- 2014-10-30 PT PT14815215T patent/PT3063151T/pt unknown
- 2014-10-30 US US15/030,879 patent/US9862723B2/en active Active
- 2014-10-30 CN CN201480059174.3A patent/CN105705505A/zh active Pending
- 2014-10-30 EP EP14815215.0A patent/EP3063151B1/en active Active
- 2014-10-30 TR TR2018/15737T patent/TR201815737T4/tr unknown
- 2014-10-30 MX MX2016005173A patent/MX2016005173A/es unknown
- 2014-10-30 LT LTEP14815215.0T patent/LT3063151T/lt unknown
-
2016
- 2016-04-20 ZA ZA2016/02731A patent/ZA201602731B/en unknown
- 2016-04-21 IL IL245263A patent/IL245263A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
PT3063151T (pt) | 2018-11-19 |
KR20160078359A (ko) | 2016-07-04 |
EP3063151A1 (en) | 2016-09-07 |
WO2015062562A1 (en) | 2015-05-07 |
ES2694350T3 (es) | 2018-12-20 |
US20160251360A1 (en) | 2016-09-01 |
EP3063151B1 (en) | 2018-08-29 |
UA119655C2 (uk) | 2019-07-25 |
CZ2013842A3 (cs) | 2015-05-13 |
CN105705505A (zh) | 2016-06-22 |
EA201690869A1 (ru) | 2016-08-31 |
IL245263A0 (en) | 2016-06-30 |
JP2016535045A (ja) | 2016-11-10 |
LT3063151T (lt) | 2018-12-10 |
PL3063151T3 (pl) | 2019-05-31 |
US9862723B2 (en) | 2018-01-09 |
ZA201602731B (en) | 2017-07-26 |
EA030029B1 (ru) | 2018-06-29 |
TR201815737T4 (tr) | 2018-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018033853A3 (en) | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | |
NZ629511A (en) | Novel crystalline form of sitagliptin sulfate | |
IL291489A (en) | Preparation of (s)-4-(8-amino-3-(1-but-2-inoyl-pyrrolidin-2-yl)imidazo[5,1-a]pyrazin-1-yl)-n-(pyridine- 2-l) Benzamide and its acceptable pharmaceutical salts | |
MY164274A (en) | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | |
BR112014032338A2 (pt) | cristais de sal | |
HRP20182007T1 (hr) | Derivati 3-okso-2,3,5,8-tetrahidro-[1,2,4]triazolo[4,3-a]pirimidina za liječenje respiratornih bolesti | |
EA201300908A1 (ru) | ПРОИЗВОДНЫЕ 6-ЦИКЛОБУТИЛ-1,5-ДИГИДРОПИРАЗОЛО[3,4d]ПИРИМИДИН-4-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE9A | |
EP3489238B8 (en) | Pharmaceutical compositions of 6h-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and [1,2,4]triazolo[1,5-c]pteridin-5(6h)-one derivatives as pde1 inhibitors for treating e.g. neurological disorders | |
WO2012143416A3 (en) | 7 - (3,5 - dimethyl - 4 - isoxazolyl) - 8 - (methyloxy) - 1h - imidazo [4,5 -c] quinoline derivatives | |
NZ601754A (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
NZ703111A (en) | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases | |
MX339302B (es) | 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina. | |
MX2020002711A (es) | Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona. | |
MX2021004487A (es) | Nuevas formas de derivados de pirido[1,2-a]pirimidin-4-ona, su formulacion y su proceso de elaboracion. | |
MX2012001529A (es) | Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-piridazin-6-ilo como moduladores de cinasa de tirosina c-met. | |
PH12015501536A1 (en) | Novel salts of dpp-iv inhibitor | |
MX2016005173A (es) | Un polimorfo estable de la sal de (2r)-4-oxo-4-[3-(trifluorometil) -5,6-dihidro[1,2,4]triazolo[4,3-a]pirazin-7(8h)-il]-1-(2,4,5-trif luorofenil)butan-2-amina con acido l-tartarico. | |
ECSP13012599A (es) | Hidrato de tartrato DE 1-{(2S)-2-amino-4-[2,4-bis(trifluorometil)-5,8-di-hidropirido[3,4-d]pirimidin-7(6H)-il]-4-oxobutil}-5,5-difluoro-piperidin-2-ona | |
MY165623A (en) | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators | |
WO2014193881A8 (en) | Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders | |
MX2023004924A (es) | Nuevo tratamiento de la atrofia muscular espinal (sma). | |
WO2015145333A8 (en) | Process for the preparation of sitagliptin and its intermediate | |
TN2013000146A1 (en) | Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | |
MX2016007494A (es) | Tratamiento de la esclerosis multiple con un derivado de 1,2,4-triazolo [1,5-a] piridina. | |
PL395783A1 (pl) | Pochodna 1,2,4-triazolo[3,4-b]-1,3,4-tiadiazolu - 3-(3-chlorofenylo)-6-(4-chlorofenylo)amino-[1,2,4]triazolo[3,4-b]-1,3,4-tiadiazol, sposób jej wytwarzania oraz jej pierwsze zastosowanie medyczne |